Patient characteristics
| . | Standard group, n = 93 . | VPA group, n = 93 . | P . |
|---|---|---|---|
| Sex, male/female | 52/41 | 46/47 | .46 |
| Age, years, median (range) | 67.6 (61.0-83.7) | 68.8 (61.5-77.6) | .45 |
| Leukocytes, 109/L | |||
| Median (range) | 13.7 (0.5-439.5) | 9.4 (0.5-196.1) | .05 |
| Missing | 1 | 1 | |
| Hemoglobin, g/dL | |||
| Median (range) | 9.4 (5.7-13.4) | 9.4 (4.4-14.5) | .53 |
| Missing | 1 | 1 | |
| Platelets, 109/L | |||
| Median (range) | 54.5 (2-294) | 47 (7-490) | .49 |
| Missing | 1 | 1 | |
| Bone marrow blasts, %* | |||
| Median (range) | 75 (15-99) | 60 (4-99) | .06 |
| Missing | 8 | 13 | |
| Peripheral blood blasts, % | |||
| Median (range) | 28 (0-99) | 22.5 (0-99) | .33 |
| Missing | 3 | 1 | |
| Hepatomegaly | |||
| n (%) | 13 (14.6) | 14 (15.7) | .99 |
| Missing | 4 | 4 | |
| Splenomegaly | |||
| n (%) | 21 (23.1) | 19 (21.1) | .85 |
| Missing | 2 | 3 | |
| Lactate dehydrogenase, U/L | |||
| Median (range) | 372 (91-3710) | 382 (102-5760) | .80 |
| Missing | 1 | 1 | |
| AML type | |||
| De novo AML, n (%) | 71 (76.3) | 69 (74.2) | |
| Secondary AML/therapy-related AML, n (%) | 21 (22.6) | 24 (25.8) | .73 |
| Missing | 1 | 0 | |
| Karyotype† | |||
| Favorable, n (%) | 5 (5.4) | 3 (3.2) | .67 |
| Intermediate, n (%) | 60 (64.5) | 54 (58.1) | |
| Adverse, n (%) | 23 (27.4) | 24 (25.8) | |
| Normal, n (%) | 41 (48.8) | 42 (51.9) | |
| Missing | 7 | 12 | |
| Nucleophosmin 1 | |||
| n (%) | 22 (25.9) | 18 (22.5) | .46 |
| Missing | 8 | 13 | |
| FLT3 internal tandem duplication | |||
| n (%) | 11 (13.1) | 12 (15.0) | .79 |
| Missing | 9 | 13 | |
| FLT3 tyrosine kinase domain mutation | |||
| n (%) | 3 (5.3) | 4 (5.1) | .30 |
| Missing | 8 | 15 |
| . | Standard group, n = 93 . | VPA group, n = 93 . | P . |
|---|---|---|---|
| Sex, male/female | 52/41 | 46/47 | .46 |
| Age, years, median (range) | 67.6 (61.0-83.7) | 68.8 (61.5-77.6) | .45 |
| Leukocytes, 109/L | |||
| Median (range) | 13.7 (0.5-439.5) | 9.4 (0.5-196.1) | .05 |
| Missing | 1 | 1 | |
| Hemoglobin, g/dL | |||
| Median (range) | 9.4 (5.7-13.4) | 9.4 (4.4-14.5) | .53 |
| Missing | 1 | 1 | |
| Platelets, 109/L | |||
| Median (range) | 54.5 (2-294) | 47 (7-490) | .49 |
| Missing | 1 | 1 | |
| Bone marrow blasts, %* | |||
| Median (range) | 75 (15-99) | 60 (4-99) | .06 |
| Missing | 8 | 13 | |
| Peripheral blood blasts, % | |||
| Median (range) | 28 (0-99) | 22.5 (0-99) | .33 |
| Missing | 3 | 1 | |
| Hepatomegaly | |||
| n (%) | 13 (14.6) | 14 (15.7) | .99 |
| Missing | 4 | 4 | |
| Splenomegaly | |||
| n (%) | 21 (23.1) | 19 (21.1) | .85 |
| Missing | 2 | 3 | |
| Lactate dehydrogenase, U/L | |||
| Median (range) | 372 (91-3710) | 382 (102-5760) | .80 |
| Missing | 1 | 1 | |
| AML type | |||
| De novo AML, n (%) | 71 (76.3) | 69 (74.2) | |
| Secondary AML/therapy-related AML, n (%) | 21 (22.6) | 24 (25.8) | .73 |
| Missing | 1 | 0 | |
| Karyotype† | |||
| Favorable, n (%) | 5 (5.4) | 3 (3.2) | .67 |
| Intermediate, n (%) | 60 (64.5) | 54 (58.1) | |
| Adverse, n (%) | 23 (27.4) | 24 (25.8) | |
| Normal, n (%) | 41 (48.8) | 42 (51.9) | |
| Missing | 7 | 12 | |
| Nucleophosmin 1 | |||
| n (%) | 22 (25.9) | 18 (22.5) | .46 |
| Missing | 8 | 13 | |
| FLT3 internal tandem duplication | |||
| n (%) | 11 (13.1) | 12 (15.0) | .79 |
| Missing | 9 | 13 | |
| FLT3 tyrosine kinase domain mutation | |||
| n (%) | 3 (5.3) | 4 (5.1) | .30 |
| Missing | 8 | 15 |